Refine search

Tumour Site

31 results for ""

Maximilian Diehn

Incorporating ctDNA into clinical trial design

ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease

By Maximilian Diehn

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.